June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Development and characterization of an iPSC-derived RPE cell model of LCHAD-associated retinopathy
Author Affiliations & Notes
  • Tiffany DeVine
    Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States
  • Garen Gaston
    Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States
  • Cary Harding
    Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States
  • Melanie Gillingham
    Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Tiffany DeVine, None; Garen Gaston, None; Cary Harding, None; Melanie Gillingham, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tiffany DeVine, Garen Gaston, Cary Harding, Melanie Gillingham; Development and characterization of an iPSC-derived RPE cell model of LCHAD-associated retinopathy. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2227.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A progressive chorioretinopathy is associated with Long-chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD). The pathophysiology of LCHADD retinopathy is incompletely understood. We have established a cell model of LCHADD to explore disease mechanisms.

Methods : Four LCHADD fibroblast lines (HADHA c.1528G>C) were reprogrammed into iPSCs. Two wild type iPSC lines were purchased as controls. iPSCs were differentiated into RPE and assayed for several RPE markers, transepithelial electrical resistance (TEER), and ability to phagocytose labeled outer segments. RPE were fed palmitate (C16) and FAO was measured with the Seahorse bioanalyzer. Acylcarnitines were measured with tandem mass spectrometry. Beta-hydroxybutyrate (BOH) was assayed from transwells. Neutral lipids were detected using LipidTOX and triglycerides were measured. RPE were treated with H2O2 and C16, viability monitored by alamarBlue.

Results : All RPE lines showed similar expression of RPE markers. Wild type and LCHADD RPE were able to phagocytose outer segments. TEER in wild type (288±13 Ω/cm2) and LCHADD (277±14 Ω/cm2) RPE was similar. The basal oxygen consumption rate (OCR) for wild type RPE increased after C16 compared to BSA alone (41 ± 6.7 BSA to 68 ± 8.5 BSA-C16, p < 0.0001). In contrast, no change was observed in LCHADD (45 ± 7.7 BSA, 51 ± 4.7 BSA-C16). Apical levels of BOH increased in wild type RPE when treated with BSA-C16 (p < 0.002) with no significant change in LCHADD RPE. Increased triglycerides and neutral lipid staining were observed only in LCHADD RPE after C16 exposure. Media from LCHADD RPE accumulated palmitoyl (C16) and 3-hydroxypalmitoyl-carnitine (C16-OH). When treated with H2O2 in the presence of C16, LCHAD RPE showed a decrease in viability compared to wild type RPE (p < 0.0001).

Conclusions : LCHADD RPE have impaired FAO and ketone body production. Acylcarnitine profiles from LCHADD RPE are similar to those of LCHADD patients. The viability of LCHADD RPE decreased when treated with H2O2 in the presence of long-chain fats. LCHADD RPE may be more susceptible to oxidative stress due to the accumulation of toxic metabolic intermediates such as C16-OH.

This is a 2021 ARVO Annual Meeting abstract.

 

Oxygen consumption rate monitored by seahorse in wild type (A, top) and LCHADD (A, bottom) RPE.

Oxygen consumption rate monitored by seahorse in wild type (A, top) and LCHADD (A, bottom) RPE.

 

(A) Apical media was assayed for BOH. (B) RPE were fed BSA or BSA-C16 for 72 hrs. followed by H2O2 treatment for 1 hr and viability was measured 24 hrs later.

(A) Apical media was assayed for BOH. (B) RPE were fed BSA or BSA-C16 for 72 hrs. followed by H2O2 treatment for 1 hr and viability was measured 24 hrs later.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×